help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dhanvantari, S.
Right arrow Articles by Brubaker, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dhanvantari, S.
Right arrow Articles by Brubaker, P. L.
Endocrinology Vol. 139, No. 4 1630-1637
Copyright © 1998 by The Endocrine Society


ARTICLES

Proglucagon Processing in an Islet Cell Line: Effects of PC1 Overexpression and PC2 Depletion1

Savita Dhanvantari2 and Patricia L. Brubaker

Departments of Physiology (S.D., P.L.B.) and Medicine (P.L.B.), University of Toronto, Toronto, Ontario M5S 1A8, Canada

Address all correspondence and requests for reprints to: Dr. P. L. Brubaker, Room 3366, Medical Sciences Building, University of Toronto, Toronto, Ontario M5S 1A8, Canada. E-mail: p.brubaker{at}utoronto.ca

Proglucagon (proG) is differentially processed in the A cells of the pancreas to yield glucagon, and in the L cells of the intestine to generate glicentin, oxyntomodulin, the incretin glucagon-like peptide (GLP)-17–36NH2 and the intestinotropin GLP-2. To establish roles for the prohormone convertases PC1 and PC2 in proG processing within the context of a physiological model, we created stable cell lines from an islet-derived cell line, InR1-G9. These cells express proG and PC2, but not PC1, messenger RNA (mRNA). InR1-G9 cells were stably transfected with PC1 or antisense PC2. Selection was carried out in G418 (InR1-G9/PC1) or Zeocin (InR1-G9/ASPC2). Both PC1 mRNA and protein were highly expressed in InR1-G9/PC1 cells (P < 0.01–0.001) compared with wild-type (WT) cells. Cells transfected with ASPC2 demonstrated significant decreases in both PC2 mRNA (P < 0.001) and protein (P < 0.05) levels. ProG-derived peptides in WT, control, InR1-G9/PC1, and InR1-G9/ASPC2 cells were identified by HPLC and RIA. Overexpression of PC1 in InR1-G9 cells resulted in increased processing to glicentin (P < 0.01), oxyntomodulin (P < 0.05), and GLP-2 (P < 0.05). Interestingly, processing to GLP-17–36NH2 did not increase upon transfection of PC1. Transfection of InR1-G9 cells with ASPC2 resulted in the disappearance of glicentin (P < 0.05). However, production of glucagon was not altered by antisense deletion of PC2. Surprisingly, GLP-17–36NH2 production appeared to be augmented (P < 0.05) in InR1-G9/ASPC2 cells, whereas GLP-2 production was not altered. In conclusion, these studies establish the role of PC1 in the processing of proG to the intestinal proG-derived peptides. This study also establishes a role for PC2 in the production of glicentin; however, the liberation of glucagon appears to be mediated by another, yet to be identified, convertase.




This article has been cited by other articles:


Home page
DiabetesHome page
R. D. Wideman, S. D. Covey, G. C. Webb, D. J. Drucker, and T. J. Kieffer
A Switch From Prohormone Convertase (PC)-2 to PC1/3 Expression in Transplanted {alpha}-Cells Is Accompanied by Differential Processing of Proglucagon and Improved Glucose Homeostasis in Mice
Diabetes, November 1, 2007; 56(11): 2744 - 2752.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
R. McGirr, C. E. Ejbick, D. E. Carter, J. D. Andrews, Y. Nie, T. C. Friedman, and S. Dhanvantari
Glucose Dependence of the Regulated Secretory Pathway in {alpha}TC1-6 Cells
Endocrinology, October 1, 2005; 146(10): 4514 - 4523.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. Dey, G. M. Lipkind, Y. Rouille, C. Norrbom, J. Stein, C. Zhang, R. Carroll, and D. F. Steiner
Significance of Prohormone Convertase 2, PC2, Mediated Initial Cleavage at the Proglucagon Interdomain Site, Lys70-Arg71, to Generate Glucagon
Endocrinology, February 1, 2005; 146(2): 713 - 727.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
J. L. Estall and D. J. Drucker
Dual Regulation of Cell Proliferation and Survival via Activation of Glucagon-Like Peptide-2 Receptor Signaling
J. Nutr., November 1, 2003; 133(11): 3708 - 3711.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
F. A. Adatia, L. L. Baggio, Q. Xiao, D. J. Drucker, and P. L. Brubaker
Cellular Specificity of Proexendin-4 Processing in Mammalian Cells in Vitro and in Vivo
Endocrinology, September 1, 2002; 143(9): 3464 - 3471.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. Dhanvantari, A. Izzo, E. Jansen, and P. L. Brubaker
Coregulation of Glucagon-Like Peptide-1 Synthesis with Proglucagon and Prohormone Convertase 1 Gene Expression in Enteroendocrine GLUTag Cells
Endocrinology, January 1, 2001; 142(1): 37 - 42.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
T. J. Kieffer and J. Francis Habener
The Glucagon-Like Peptides
Endocr. Rev., December 1, 1999; 20(6): 876 - 913.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
A. B. Damholt, A. M. J. Buchan, J. J. Holst, and H. Kofod
Proglucagon Processing Profile in Canine L Cells Expressing Endogenous Prohormone Convertase 1/3 and Prohormone Convertase 2
Endocrinology, October 1, 1999; 140(10): 4800 - 4808.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1998 by The Endocrine Society